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doi:10.1016/j.jtcvs.2003.12.0371256 The Journal of Thoracic and CardIn their two articles published in the November issue of the Journal,1,2 thegroup from the Children’s Hospital in Boston have provided us with thebest clinical data available comparing deep hypothermic circulatory arrest(DHCA) with hypothermic, continuous low-flow bypass (LF)—2 cardio-pulmonary bypass (CPB) strategies that are commonly used during therepair of congenital heart defects in infants.
It is relevant to provide a brief historical perspective regarding how and why
these studies were designed. DHCA became popular after its use was reported by
Kirklin and associates3 in 1961 and later in neonates and infants by Barratt-Boyes
and associates in 19704 because it greatly simplified cardiac repair in infants in an
era that did not have the sophisticated CPB technology (including thin-walled
cannulas with excellent flow characteristics, smaller circuits with membrane oxy-
genators, and much more) that we enjoy today. By using DHCA, surgeons could
repair intracardiac defects in a bloodless field unencumbered by cannulas. Further-
more, surgeons avoided many of the complications created by the more primitive
CPB systems, and this most likely produced success in an era when prolonged
exposure to CPB was very likely detrimental. Results were generally favorable, and
the use of DHCA made cardiac repair in infants reproducibly possible. As technol-
ogy improved and surgeons began to tackle repair of more complex lesions, DHCA
became a staple in the armamentarium of cardiac surgeons. Its use became so
ingrained in the practice patterns of cardiac surgeons that it was unusual in the 1980s
to find successful pediatric cardiac centers anywhere in the world that did not use
DHCA on a routine basis.
By the late 1980s, the seeds of concern were germinating regarding the effect of
DHCA on the neurologic development of the infants exposed to it. This marked a
subtle, but substantial, shift in cardiac surgery for infants—the field was beginning
to focus on long-term quality of life rather than just on initial survival. Compared
with mortality rates in the earlier days of surgery for congenital heart disease, which
were high, mortality after infant heart surgery was becoming less frequent, and rates
were comparable with those experienced for adults having more routine procedures
(such as coronary artery bypass grafting)—all despite the increasing complexity of
defects being repaired by congenital heart surgeons. It was an important era because
it heralded the development of so many techniques that we consider commensurate
with modern infant heart surgery. Surgeons were shifting to primary repair versus
palliation of repairable defects because systems allowed this with predictable
survival. Membrane oxygenators; improved methods of myocardial protection;
more finely engineered surgical instruments, cannulas, and sutures; and improved
prosthetic materials, along with numerous other advances in technology and surgical
experience, were enabling surgeons to rethink the systems and techniques that their
infant patients were exposed to during surgical reconstruction.
Understanding of the “safe” period of DHCA was still evolving. In general, it
was considered acceptable to expose infants to circulatory arrest for as long as 45
to 60 minutes at 18°C.5 Reports appeared in the literature that attempted to
characterize the effect of DHCA on neurodevelopmental outcome.6-9 For the most
part, these reports were retrospective, noncontrolled reviews of neurologic outcomes
for widely dissimilar patients, and they generated increasing concern that DHCA
might be associated with movement disorders such as choreoathetosis and with
10-17generalized poor neurodevelopmental outcomes. Against the backdrop of these
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Lretrospective clinical reviews, a few studies were being
performed to elucidate the nature of physiologic alterations
that occurred within the brain after DHCA,18-44 and these
studies led to important changes in the application of DHCA
that have today changed the expectations from DHCA.
It was during this time that the group at Children’s
Hospital in Boston was experiencing internationally recog-
nized success with neonatal arterial switch for transposition
of the great arteries. They had the great fortune of receiving
a large cohort of infants who had the same defect, and
fortunately, they had the foresight to randomize these pa-
tients into 2 general groups—those who had repair per-
formed with the use of a prolonged period of DHCA and
those whose repair was performed with the use of predom-
inately continuous LF (“LF” in the 8-year follow-up study
and “E” in the duration study).1,2 DHCA was used only
briefly during closure of atrial and (when present) ventric-
ular septal defects. These two recently published companion
articles1,2 have granted us a unique opportunity to examine
the outcome for those patients 8 years after their enrollment
in this study, and the results provide important insight into
what might be expected from a neurobehavioral standpoint
in patients who undergo either of these 2 strategies.
Despite the anxiety that has developed in more recent
years about the use of DHCA and the enthusiasm expressed
by some groups that DHCA should be avoided in favor of
continuous low-flow perfusion,45,46 the neurologic testing
performed at a mean of 8 years after exposure to these 2
CPB strategies failed to show a significant difference be-
tween groups.2 Each group has its own behavioral signature,
which suggests a subtle difference between the effect of
strategies that predominantly use DHCA and those that
primarily use LF, but it is important to note that the treat-
ment groups did not significantly differ in full-scale IQ,
performance IQ, memory screening index, Wechsler Indi-
vidual Achievement Test summary scores or subscales, the
Wisconsin Card Sorting test, visual-spatial or visual-motor
skills (although the cohort as a whole was in the 25th
percentile), or the proportion of children judged to have a
possible or a definite abnormality (however, the frequency
of abnormalities was high in both groups compared with the
normal population). The DHCA group fared worse than the
LF group in areas such as manual dexterity (with the non-
dominant hand), speech, visual-motor tracking, and phono-
logic awareness (a skill considered important for the devel-
opment of reading skills). The LF group was significantly
more impaired in measurements of attention and behavior
(as graded by teachers). However, the data, when consid-
ered for both groups, demonstrate that regardless of the CPB
strategy used, both groups were impaired compared with
healthy subjects, but neither was more impaired than the
other.
The Journal of ThoracicThe companion article on the effects of duration of
DHCA1 suggests that if the patients with DHCA times
longer than 41 minutes were removed from the total DHCA
group, the neurodevelopmental effects would be even less
pronounced. Neurodevelopmental outcomes were generally
not adversely affected unless the duration of DHCA exceed
a threshold of 41 minutes. By comparing groups with a
model that analyzed outcome data for various cut points, the
authors found no association between duration of DHCA
and outcome if the DHCA time was less than 41 minutes. If
the duration of DHCA exceeded 41 minutes, there was a
significant association between duration of DHCA and out-
come in 5 areas: full-scale IQ, verbal IQ, performance IQ,
grooved pegboard (a test of motor skills), and the Mayo test
of apraxia. They also pointed out the important feature that
these findings were produced by application of DHCA in an
era (1988-1992) when the typical strategy used exposure to
alpha-stat cooling, hemodilution to hematocrits of 20%,
outmoded hardware, and no arterial filters, thus implying
that outcomes might be different in a more modern era.
How should practitioners interpret the data from these
studies? How should these studies influence our practice in
2004, and can we come to any conclusion regarding whether
or not DHCA should be used in a modern era?
First, it should be recognized that most children in the
Boston review performed well within the normal range.
This is hopeful, especially in light of the improvements that
have been made in our strategies since this study was
designed. It is comforting to know that our selection of CPB
repair strategy in the early 1990s did not create significant
neurologic issues for survivors compared with the various
commonly used strategies that were available to us.
However, before we ignore the findings of these studies
as inconclusive, we should pay careful attention to the fact
that more than one third of children (although there was no
difference between DHCA and LF) were identified as re-
quiring remedial academic services and that this may even-
tually be correlated with problems in executive function,
such as organizing and implementing strategies and plans
and modifying them as needed. Both groups are impaired
compared with normal children, signifying that if this is
related to CPB, our strategies need to improve. Although
there are ample data (some of which are cited in these
studies) to imply that long-term neurologic outcome may be
related to underlying defects—as opposed to CPB strategy
(eg, the presence of a ventricular septal defect, socioeco-
nomic class of patients, the presence of preoperative hypox-
emia, or the postoperative hemodynamic status), there is a
disturbing reality that our CPB systems are still responsible
for some of the outcome that can be measured in survivors
of neonatal cardiac repair. We have an opportunity to im-
prove. Data looking at cognitive outcome in adults after
coronary artery bypass graft surgery and from children
and Cardiovascular Surgery ● Volume 127, Number 5 1257




Lundergoing surgical versus catheterization laboratory clo-
sure of atrial septal defects imply that CPB itself may be a
risk factor for neurologic outcome.47,48 Indeed, the Boston
authors did not have a neonatal CPB control for their
studies, and using non-CPB controls may not be appropriate
in terms of arriving at conclusions regarding the effects of
DHCA and LF. CPB may itself be a major factor in what
happens over the long term to our patients, whether we
choose to use DHCA or LF. Recent data from Galli and
colleagues at Children’s Hospital of Philadelphia indicate
that application of CPB to neonates may be a risk factor for
neurologic outcome.49 This study evaluated the incidence of
cerebral white matter injury after neonatal and infant car-
diac surgery. White matter injury was common in neonates
(50%) but rare in older infants (4%). Immaturity of the
brain, particularly oligodendrocytes, may increase the risk
of CPB-induced injury.
In addition, some patients may be at increased risk of
injury secondary to genetic factors. Polymorphisms of apo-
lipoprotein E (APOE) have been identified as a risk factor
for worse neurologic recovery after a variety of central
nervous system injuries. A recent single-institution prospec-
tive study of patients 6 months of age or younger undergo-
ing CPB for repair of congenital heart disease demonstrated
a significant association between APOE genotype and post-
operative neurodevelopmental dysfunction. APOE 2 allele
carriers had significantly lower Psychomotor Development
Index scores at 1 year of age after having cardiac surgery as
infants. The effect is independent of ethnicity, socioeco-
nomic status, cardiac defect, and use of DHCA. Thus,
genetic polymorphisms that decrease neuroresiliency and
impair neuronal repair after central nervous system injury
are important risk factors for neurodevelopmental dysfunc-
tion after infant cardiac surgery and may be critical to
neurodevelopmental outcome regardless of the CPB strat-
egy used.49,50
Fortunately, as implied by the authors in the study on
DHCA duration,1 our systems have improved. The findings
described in both Boston studies1,2 were the result of his-
torical CPB and DHCA strategies that have been signifi-
cantly improved over the past decade. In a recent review by
Menasche´ and colleagues,51 the observed incidence of ob-
jective manifestations of brain injury after operations in
children (eg, seizures, movement disorders, or coma) have
been substantially reduced compared with what was seen in
the late 1980s and early 1990s—the time frame for patient
enrollment in these 2 studies on DHCA versus LF. We can
infer from this that CPB has become safer from a neurologic
perspective. This is not an unrealistic inference. There have
been numerous improvements in neonatal CPB in the past
decade.52,53 Some of these have been related to advances in
technology and some to research-driven changes in the way
that DHCA and neonatal CPB are applied. With recognition
1258 The Journal of Thoracic and Cardiovascular Surgery ● Maand control of the inflammatory effects of CPB on neonates,
their response to CPB has improved, and this has undoubt-
edly affected neurologic responses.54-57 We can conjecture
that on the basis of the ability to better harness the inflam-
matory effects of CPB, neurologic outcome after exposure
to LFCPB might be better than that described for the pa-
tients in the Boston Children’s study. However, it is very
likely that the outcome after exposure to DHCA is even
better. For one thing, patients exposed to DHCA will benefit
from the same advances in CPB that have evolved over the
past decade. In addition, there have been numerous ad-
vances in the understanding of how to improve brain pro-
tection during exposure to DHCA. Restudying a cohort of
patients in the modern era, with a protocol similar to that
used in the Boston Children’s transposition of the great
arteries study, might actually demonstrate an advantage for
DHCA if the strategy used currently recommended tech-
niques.
Our current understanding of DHCA uses a variety of
strategies, including using preoperative steroids54,58; recog-
nizing high-risk groups35,52 (such as those with aortopul-
monary collaterals or those who will have postoperative
hypoxemia); providing adequate duration of pre-DHCA
cooling,11,27 often with cooling to temperatures less than
18°C20,42; and using a pH-stat as opposed to alpha-stat
blood gas strategy.18,20,36,40,42,59 Preoperative hyperoxygen-
ation has been recommended for infants who will be ex-
posed to longer durations of DHCA,60 and some recom-
mend conversion to alpha-stat (after pH-stat) cooling just
before DHCA.40 Perhaps the most significant recommenda-
tion that can affect the outcome after DHCA, especially in
light of the findings related to duration of DHCA and
outcome, is to limit the exposure to DHCA to only those
periods when it is necessary or to provide some form of
cerebroplegia. Intermittent perfusion, between DHCA peri-
ods limited to 15 to 20 minutes, may virtually abolish the
neurologic injury seen after exposure to DHCA.37 After
DHCA, the use of modified ultrafiltration41 and, especially,
protection of postoperative hemodynamics, including the
use of extracorporeal life support (extracorporeal membrane
oxygenation or ventricular assist device)52 may be particu-
larly beneficial in protecting the brain from injury. There is
little question that the application of DHCA in 2004 is far
safer and better understood than it was in the time frame that
this study was conducted, and it may be that a repeat of the
investigation would show very little difference from nor-
mal. In fact, preliminary data suggest this to be the case,
even in a high-risk population such as those infants with
hypoplastic left heart syndrome undergoing the Norwood
procedure.61
The authors also contend, from reviewing their outcomes
1in the article on duration of DHCA, that their “findings
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Lindicate that neurodevelopmental sequelae of DHCA are
related to its duration in a nonlinear fashion.” They base this
contention on their outcomes versus “cut points.” We urge
caution with this interpretation. Ischemia causes a dose-
related injury in almost any model that has been closely
studied. In fact, metabolic studies of brain recovery after
exposure to DHCA verified this phenomenon in a neonatal
model exposed to varying durations of DHCA.38 It may be
that it takes a threshold of injury to the brain before func-
tional effects become apparent, but this does not mean that
damage has not occurred. This underscores the very impor-
tant limitation in any study of neurologic function after
exposure to the systems we use for infant heart repair.
Unlike our ability to study myocardial function, which is
relatively easy to evaluate in terms of systolic and diastolic
function, cerebral function is mired in complexity. There are
so many functions to the brain—motor, sensory, cognitive,
and so on—that the authors had to use a plethora of tests to
uncover the effects of CPB strategies, and it is still not
possible to distinguish the effects of DHCA or LFCPB from
all the other elements that might affect long-term brain
function.
What we can say is that we need to respect the enormous
physiologic extremes that our infant patients are exposed to
during our attempts to repair their heart defects. Although
armchair reasoning might lead us to assume that continuous
LF would be superior to DHCA, the data do not support
this—neither the data from animal research laboratories nor
the data provided in this, the best available, outcome study
of neurodevelopmental outcomes for our infant patients. We
also have to be careful not to use the outcome data from
these studies to support complacency. Both groups studied
were impaired. We can and should improve. Perhaps we
already have. DHCA probably causes a dose-related isch-
emic injury to the brain that can be attenuated by numerous
contemporary strategies and that can be virtually eliminated
by periodic cerebral reperfusion to limit the ischemic insult.
LFCPB extends the inflammatory effects of CPB on the
brain, and this may counter the predicted advantage of
avoiding ischemia. It is likely that we will learn better
methods of diminishing this problem in the years ahead.
Current work with miniaturized circuitry that avoids the
need for blood transfusion in neonatal animals shows sub-
stantial promise in this arena. The updated Boston circula-
tory arrest studies recently published in the Journal1,2 nei-
ther support nor reject the use of either DHCA or LFCPB as
a preferred strategy for infant heart repair. This is an emo-
tionally charged issue for some centers, but the reality is that
in 2004, there is ample evidence to support the use of either
strategy and optimism that continued investigation will help
us further refine neonatal CPB so that outcomes will get
even better in the future.
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